Pfeiffenberger Brent 4

What Happened

• Brent Pfeiffenberger, President, CEO and a director of Century Therapeutics (IPSC), received compensation awards on Feb 2, 2026 consisting of 475,000 restricted stock units (RSUs) and 945,000 derivative/option-style awards. Both awards were granted at $0.00 per share (i.e., they are compensation grants, not purchases), and the filing records $0 cash paid.

Key Details

• Transaction date and price: 2026-02-02, granted at $0.00 per share (award/grant)
• Total instruments granted: 475,000 RSUs + 945,000 derivative awards = 1,420,000 total
• Vesting / settlement:
  • RSUs (475,000): vest 25% on Feb 2, 2027, then the remaining 75% vest quarterly over the following three years; RSUs will be settled in common shares at each vesting date (Footnote F1).
  • Option-style award (945,000): vests 25% on Feb 2, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter (Footnote F2).
• Shares owned after transaction: not disclosed in the Form 4 filing
• Filing timeliness: reported on Form 4 filed Feb 4, 2026 for a Feb 2, 2026 grant — appears timely under the two-business-day requirement
• No sales, exercises, or tax-withholding transactions were reported in this filing

Context

• These grants are standard equity compensation for executives and are subject to service-based vesting; they do not represent an immediate purchase of publicly traded shares. RSUs convert to actual shares only when they vest; option-style awards must vest before they can be exercised. Such awards can dilute shareholders when settled, but they are a routine part of executive pay and do not by themselves indicate buying or selling sentiment.